Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2019
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2019
SUMMARY
According to the recently published report 'Leptin Receptor - Pipeline Review, H1 2019'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 7 molecules.
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.
The report 'Leptin Receptor - Pipeline Review, H1 2019' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I and Preclinical stages are 1 and 6 respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Oncology and Ophthalmology which include indications Obesity, Lipodystrophy (Lipoatrophy), Alzheimer's Disease, Breast Cancer, Choroidal Neovascularization, Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Leptin Receptor - Pipeline Review, H1 2019'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 7 molecules.
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.
The report 'Leptin Receptor - Pipeline Review, H1 2019' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I and Preclinical stages are 1 and 6 respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Oncology and Ophthalmology which include indications Obesity, Lipodystrophy (Lipoatrophy), Alzheimer's Disease, Breast Cancer, Choroidal Neovascularization, Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
- The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development
Jyant Technologies Inc
Neurotez Inc
Regeneron Pharmaceuticals Inc
XL-protein GmbH
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles
Allo-Aca - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
memtin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metreleptin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-4461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones
Featured News & Press Releases
Aug 23, 2018: Novelion Therapeutics announces next phase of operational improvements
Jul 31, 2018: Novelion Therapeutics Announces Marketing Authorization for MYALEPTA (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy
Jun 25, 2018: Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
Jun 01, 2018: MYALEPTA (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
Sep 15, 2017: Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology
Jun 12, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
May 05, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
Apr 04, 2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society
Mar 30, 2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
Jan 23, 2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency
Dec 22, 2016: Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy
Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff as Executive Vice President Head of R&D
Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff as Executive Vice President, Head of R&D
Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff, M.D., as Executive Vice President, Head of R&D
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development
Jyant Technologies Inc
Neurotez Inc
Regeneron Pharmaceuticals Inc
XL-protein GmbH
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles
Allo-Aca - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
memtin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metreleptin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-4461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones
Featured News & Press Releases
Aug 23, 2018: Novelion Therapeutics announces next phase of operational improvements
Jul 31, 2018: Novelion Therapeutics Announces Marketing Authorization for MYALEPTA (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy
Jun 25, 2018: Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
Jun 01, 2018: MYALEPTA (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
Sep 15, 2017: Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology
Jun 12, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
May 05, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
Apr 04, 2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society
Mar 30, 2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
Jan 23, 2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency
Dec 22, 2016: Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy
Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff as Executive Vice President Head of R&D
Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff as Executive Vice President, Head of R&D
Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff, M.D., as Executive Vice President, Head of R&D
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Jyant Technologies Inc, H1 2019
Pipeline by Neurotez Inc, H1 2019
Pipeline by Regeneron Pharmaceuticals Inc, H1 2019
Pipeline by XL-protein GmbH, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Jyant Technologies Inc, H1 2019
Pipeline by Neurotez Inc, H1 2019
Pipeline by Regeneron Pharmaceuticals Inc, H1 2019
Pipeline by XL-protein GmbH, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
COMPANIES MENTIONED
Jyant Technologies Inc
Neurotez Inc
Regeneron Pharmaceuticals Inc
XL-protein GmbH
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
COMPANIES MENTIONED
Jyant Technologies Inc
Neurotez Inc
Regeneron Pharmaceuticals Inc
XL-protein GmbH
